OBJECTIVE:To isolate and identify lignans chemical constituents from Coptis chinensis,and to investigate their in-hibitory activities to protein tyrosine phosphatase-1B (PTP1B). METHODS:The acetic ether part of 95% ethanol extract from C. chinensis was isolated by HPLC and gel column chromatography,and the structure of chemical constituents were identified by UV, IR,MS and NMR. Using RK-682 as positive drug,the inhibitory activity to PTP1B was investigated(the concentrations of posi-tive drug and isolated chemical constituents were 0,15,30,50,65,80,100,120,140,170 and 200 μmol/L,respectively). In-hibitory rate and IC50 of them were calculated. RESULTS:5 lignans were isolated,including 9-acetyl lanicepside B,Lanicepside A,Woorenogenin,(+)-isolariciresinol and(+)-lariciresinol gluciside(compound 1-5),and compound 1 and 2 were isolated from C. chinensis for the first time. Compound 1-5 inhibited PTP1B to certain extent in concentration-dependent manner. IC50 of them were 57,49,71,58 and 51 μmol/L,but their effects were not as good as RK-682 (IC50=32 μmol/L). CONCLUSIONS:5 lig-nans have been isolated from C. chinensis and can inhibit PTP1B to certain extent.

Objective To examine the clinical characteristics,treatment,and prognosis of patients with synchronous head and neck and esophageal cancer (SHNEC).Methods The clinical data of 30 SHNEC patients treated in the Department of Radiotherapy of the First Affiliated Hospital of China Medical University from 2010 to 2014 were retrospectively reviewed.The patients were followed up and survival was calculated using the Kaplan-Meier method.Differences between survival curves were analyzed by the log-rank test,and prognostic analysis was performed using the Cox regression model.At the same and different time,the comprehensive diagnosis were 24 cases and 6 cases.21 patients were treated with radiochemotherapy, 9 patients were treated by surgery and radiotherapy±chemotherapy.Results SHNEC was frequently found in elderly men with heavy drinking and smoking habits.Hypopharyngeal cancer with middle esophageal cancer was most common among the patients;of the 30 patients,23(77%) had hypopharyngeal cancer,and 12(40%) had hypopharyngeal cancer with middle esophageal cancer.The median survival time of the patients was 20 months,and the 1-and 2-year overall survival (OS) rates were 83% and 37%,respectively.Univariate analysis showed that the stage of esophageal cancer,heavy smoking and drinking habits,and a family history of cancer were significantly associated with patient prognosis (P=0.009,0.044,0.012).In addition,the Cox analysis also demonstrated that the stage of esophageal cancer (HR=3.53,P=0.008),heavy smoking and drinking habits (HR=2.33,P=0.049),and a family history of cancer (HR=2.78,P=0.026) were independent prognostic factors.Conclusions Hypopharyngeal and middle esophageal cancer is the most common type of SHNEC,and the stage of esophageal cancer and heavy smoking and drinking habits are significantly associated with the prognosis of SHNEC patients.In addition,patients with stage Ⅰ and Ⅱ esophageal cancer can also achieve acceptable survival after receiving radiotherapy-based comprehensive treatment.

Objective:To detect the anti-cancer component, trans-resveratrol in red wine by high performance liquid chromatography, and to determine the influence of environmental factors on its content. Methods: A method for determining trans-resveratrol in red wine by HPLC is described. The operating conditions were ZORBAX-C18 column(4.6 mm×250 mm, 5μm) at room temperature, 30%acetonitrile as mobile phase at a flow of 1ml/min and UV detection at 306 nm. Results:The content of trans-resveratrol in Changyu dry red wine and Great Wall Claret Cabernet are (1.01±0.03)mg/L and (2.36±0.02)mg/L, respectively. The results show that, sunlight, high temperature and poor seal condition can decrease the content of trans-resveratrol. Conclusion:The content of trans-resveratrol varies in different brands of red wine. Red wine should be stored in cool, dark and sealed conditions.

A type of data acquisition system of Laplacian ECG based on USB is introduced in this paper. The principle of hardware and method of software designing are explained. This system not only possesses very high CMRR, but also realizes the collection and transmission of Laplacian ECG signals in real time. This system is valuable in practice.

Objective To explore the features of verbal working memory in elderly patients with anmestic mild cognitive impairment (aMCI).Methods Thirty patients with aMCI and 30 normal controls (NC), whose age were over 65 years old, were examined with verbal working memory software and the other neuropsychological tests, such as verbal fluency test (VFT) and digit span test.Results The correct rate of visual semantic verbal working memory test was significantly lower in aMCI patients (79.83% ± 3.22% )than in NC ( 87.00% ±: 1.93 % , t = - 1.03, P = 0.002).There was no significant difference of correct rate of the visual phonological verbal working memory test between the aMCI (78.92% ± 8.60% ) and NC (86.80% ±2.14%, t = - 2.34, P = 0.060).Also, aMCI cases achieved significantly lower scores than NC on VFT (22.96 ±2.31 vs 31.53 ±3.72, t = - 1.08, P =0.004) and BDS ( 1.53 ±0.86 vs 3.63 ±0.56, t = - 1.23, P = 0.027).Conclusion The visual semantic verbal working memory is impaired and visual phonetic working memory is saved in aMCI patients.Both scores of verbal fluency test and digit span test are significantly decreased in aMCI patients, too.

Objective To evaluate the long-term results of rapamycin eluting stent in patients with coronary heart disease.Methods From Dec. 2001 to Nov. 2002, 143 patients were treated with 173 rapamycin eluting stents. Sixteen stents were implanted directly, the others were implanted with pre-dilation. Post-dilations were performed in 52 stents. All patients were administered aspirin and clopidogrel regularly before and after the procedures. Results Procedural succees rate reached 99.3% with completion of the follow-up in 138 patientes averaging (12.8 ?4.3) months. Thirteen patients has suffered with recurrent angina and 1 had acute myocardial infarction. Thirty eight patients received repetition of coronary angiography within 6 to 12 months after the procedure. Five patients showed instent restenosis, of which 4 received target lesion revascularization. The restenosis rate was 13.2% by angiography.Conclusion Rapamycin eluting stent can be used safely and effectively in patient with coronary heart disease, having long-term effect to reduce the restenosis rate after PCI.

Dendritic cells (DCs) are potent antigen presenting cells with dual functions in immune response or im-mune tolerance. Regulatory dendritic cells (DCreg) have negative immunomodulation effects. They can inhibit T cell stimula-tory activity and induce immune tolerance. DCreg can be generated by the induction of drugs, cytokines and cell microenvi-ronment with different mechanisms. DCreg induced tolerance is of great clinical significance in organ transplantation and au-toimmune disease. Recently, several clinical trials have been conducted in type 1 diabetes and rheumatoid arthritis, with re-sults that emphasize the tolerance and safety of DCreg therapy. In this review, we will focus on the strategies for generating DCreg and the clinical application of immune tolerance.

In the last twenty years, using all-trans retinoic acid (ATRA) as a differentiation inducer, Shanghai Institute of Hematology has achieved an important breakthrough in the treatment of acute promyelocytic leukemia (APL), which realized the theory of reversing phenotype of cells and provided a successful model of differentiation therapy in cancers. Our group first discovered in the world the variant chromosome translocation t(11;17)(q23;q21) of APL, and cloned the PML-RAR alpha, PLZF-RAR alpha and NPM-RAR alpha fusion genes corresponding to the characterized chromosome translocations t(15;17); t(11;17) and t(5;17) in APL. Moreover, establishment of transgenic mice model of APL proved their effects on leukemogenesis. The ability of ATRA to modify the recruitment of nuclear receptor co-repressor with PML-RAR alpha but not PLZF-RAR alpha caused by the variant chromosome translocation elucidated the therapeutic mechanism of ATRA from the molecular level and provides new insight into transcription-modulating therapy. Since 1994, our group has successfully applied arsenic trioxide (As(2)O(3)) in treating relapsed APL patients, with the complete remission rate of 70% - 80%. The molecular mechanism study revealed that As(2)O(3) exerts a dose-dependent dual effect on APL. Low-dose As(2)O(3) induced partial differentiation of APL cells, while the higher dose induced apoptosis. As(2)O(3) binds ubiquitin like SUMO-1 through the lysine 160 of PML, resulting in the degradation of PML-RAR alpha. Taken together, ATRA and As(2)O(3) target the transcription factor PML-RAR alpha, the former by retinoic acid receptor and the latter by PML sumolization, both induce PML-RAR alpha degradation and APL cells differentiation and apoptosis. Because of the different acting pathways, ATRA and As(2)O(3) have no cross-resistance and can be used as combination therapy. Clinical trial in newly diagnosed APL patients showed that ATRA/As(2)O(3) in combination yields a longer disease-free survival time. With the median survival of 18 months, none of the 20 cases in combination treatment relapsed, whereas 7 relapsed in 37 cases in mono-treatment. This is the best clinical effect achieved in treating adult acute leukemia to this day, possibly making APL the first adult curable leukemia. Based on the great success of the pathogenetic gene target therapy in APL, this strategy may extend to other leukemias. Combination of Gleevec and arsenic agents in treating chronic myeloid leukemia has already make a figure both in clinical and laboratory research, aiming at counteracting the abnormal tyrosine kinase activity of ABL and the degradating BCR-ABL fusion protein. In acute myeloid leukemia M(2b), using new target therapy degradating AML1-ETO fusion protein and reducing the abnormal tyrosine kinase activity of c-kit will also lead to new therapeutic management in acute leukemias.
Antineoplastic Agents ; therapeutic use ; Benzamides ; Fusion Proteins, bcr-abl ; genetics ; metabolism ; Humans ; Imatinib Mesylate ; Leukemia, Promyelocytic, Acute ; drug therapy ; genetics ; metabolism ; Oncogene Proteins, Fusion ; genetics ; metabolism ; Piperazines ; therapeutic use ; Protein-Tyrosine Kinases ; antagonists & inhibitors ; metabolism ; Pyrimidines ; therapeutic use ; Receptors, Retinoic Acid ; genetics ; metabolism ; Tretinoin ; therapeutic use

Acute Kidney Injury ; blood ; physiopathology ; therapy ; Blood Pressure ; Critical Illness ; therapy ; Electrolytes ; blood ; Female ; Hemofiltration ; methods ; Humans ; Infant ; Male ; Prognosis